Global Scleroderma Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Scleroderma Therapeutics Market Growth (Status and Outlook) 2023-2029

Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.

LPI (LP Information)' newest research report, the “Scleroderma Therapeutics Industry Forecast” looks at past sales and reviews total world Scleroderma Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Scleroderma Therapeutics sales for 2023 through 2029. With Scleroderma Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Scleroderma Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Scleroderma Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Scleroderma Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Scleroderma Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Scleroderma Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Scleroderma Therapeutics.

The global Scleroderma Therapeutics market size is projected to grow from US$ 1371.8 million in 2022 to US$ 1748.5 million in 2029; it is expected to grow at a CAGR of 3.5% from 2023 to 2029.

The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis.

This report presents a comprehensive overview, market shares, and growth opportunities of Scleroderma Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Immunosuppressors
Phosphodiesterase 5 Inhibitors - PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Analgesics
Others

Segmentation by application
Systemic
Localized

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex

Please note: The report will take approximately 2 business days to prepare and deliver.